Drugs / Investigational COVID-19 Vaccine
Investigational COVID-19 Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06821061 | Feb → Dec 2025 | COVID-19, influenza | BioNTech SE | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-02-01 | BioNTech SE | Pfizer and BioNTech Publish Preclinical Data from Investigational COVID-19 Vaccine Program in Nature biontech.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Investigational COVID-19 Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06821061 ↗ |
| Modality | Messenger RNA (mRNA) | “modified RNA vaccine candidates against influenza and COVID-19” NCT06821061 ↗ |